Drug firm AstraZenecaPharma India Ltd on Thursday (November 5) reported a 14.9% year-on-year increase in net profit to ₹62.3 crore for the second quarter of FY27, compared with ₹54.2 crore in the corresponding quarter last year.
Revenue from operations grew 30.4% to ₹729 crore from ₹559 crore.
Earnings before interest, tax, depreciation and amortisation (EBITDA) increased 26.7% to ₹95 crore from ₹75 crore. However, EBITDA margin contracted to 13.1% from 13.4% in the year-ago quarter.
ALSO READ | AstraZeneca Pharma India gets CDSCO nod for expanded use of breast cancer drug Enhertu
The company said its revenue grew 30% in Q2 FY27, supported by consistent performance across its oncology, biopharmaceuticals and rare disease therapy areas.
Revenue from operations for the first half of FY27 reached ₹1,411.9 crore (₹14,119 million), registering 30% growth compared with the corresponding period of the previous financial year.
Regulatory approvals
During the quarter, AstraZeneca Pharma received regulatory approval for trastuzumab deruxtecan in multiple breast cancer treatment settings.
The approvals include trastuzumab deruxtecan followed by taxane, trastuzumab and pertuzumab (THP) for adults with HER2-positive Stage II or III early breast cancer.
ALSO READ | AstraZeneca Pharma India gets CDSCO nod to import and distribute breast cancer treatment drug
The company also received approval for trastuzumab deruxtecan for adults with HER2-positive early breast cancer who have residual invasive disease following neoadjuvant treatment.
Another approval covers trastuzumab deruxtecan in combination with pertuzumab for the first-line treatment of adults with unresectable or metastatic HER2-positive breast cancer, with immunohistochemistry (IHC) 3+ or in situ hybridisation (ISH)-positive status.
AstraZeneca Pharma also received regulatory approval for benralizumab for patients aged 12 years and older with hypereosinophilic syndrome (HES) without an identifiable non-haematologic secondary cause.
Praveen Rao Akkinepally, Country President and Managing Director, AstraZeneca Pharma India Ltd, said, “The continued growth demonstrates the strength of AstraZeneca’s science-led portfolio and our ability to translate innovation into meaningful impact for patients in India.
ALSO READ | AstraZeneca Pharma gets CDSCO nod to import leukaemia drug Calquence 100 mg tablets
We are accelerating our efforts across oncology, biopharmaceuticals and rare disease. Our focus remains on building strong partnerships across the healthcare ecosystem to bring innovative medicines to more patients faster and improve health outcomes across the country.”
Shares of AstraZeneca Pharma India Ltd ended at ₹6,285.20, down by ₹79.90, or 1.26%, on the BSE.